Suppr超能文献

一款具备细胞功能的血糖仪对糖尿病患者血糖控制的影响:前瞻性前后对照研究。

The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study.

作者信息

Bollyky Jennifer B, Melton Stephanie T, Xu Tong, Painter Stefanie L, Knox Brian

机构信息

Stanford University School of Medicine, Stanford, CA, United States.

University of South Florida, Florida, CA, United States.

出版信息

JMIR Diabetes. 2019 Oct 7;4(4):e14799. doi: 10.2196/14799.

Abstract

BACKGROUND

Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitoring technology with Certified Diabetes Educator outreach.

OBJECTIVE

The purpose of this study was to examine health outcomes measured by changes in HbA, in time in target blood glucose range, and in depression symptoms for patients enrolled in a remote digital diabetes management program in a Diabetes Center of Excellence setting.

METHODS

The impact of the Livongo for Diabetes program on hemoglobin A (HbA), blood glucose ranges, and depression screening survey results (Patient Health Questionnaire-2 [PHQ-2]) were assessed over 12 months in a prospective cohort recruited from the University of South Florida Health Diabetes Home for Healthy Living. Any patient ≥18 years old with a diagnosis of diabetes was approached for voluntary inclusion into the program. The analysis was a pre-post design for those members enrolled in the study. Data was collected at outpatient clinic visits and remotely through the Livongo glucose meter.

RESULTS

A total of 86 adults were enrolled into the Livongo for Diabetes program, with 49% (42/86) female, an average age of 50 (SD 15) years, 56% (48/86) with type 2 diabetes mellitus, and 69% (59/86) with insulin use. The mean HbA drop amongst the group was 0.66% (P=.17), with all participants showing a decline in HbA at 12 months. A 17% decrease of blood glucose checks <70 mg/dL occurred concurrently. Participants with type 2 diabetes not using insulin had blood glucose values within target range (70-180 mg/dL) 89% of the time. Participants with type 2 diabetes using insulin were in target range 68% of the time, and type 1 diabetes 58% of the time. Average PHQ-2 scores decreased by 0.56 points during the study period.

CONCLUSIONS

Participants provided with a cellular-enabled blood glucose meter with real-time feedback and access to coaching from a certified diabetes educator in an outpatient clinical setting experienced improved mean glucose values and fewer episodes of hypoglycemia relative to the start of the program.

摘要

背景

糖尿病是一种全球性流行病,在美国约影响3000万人。世界卫生组织建议利用技术和电信来改善医疗服务提供和疾病管理。Livongo糖尿病项目提供一种远程监测技术,并配备有认证糖尿病教育者进行推广。

目的

本研究的目的是在一家卓越糖尿病中心环境下,对参加远程数字糖尿病管理项目的患者,通过糖化血红蛋白(HbA)变化、处于目标血糖范围的时间以及抑郁症状来衡量健康结局。

方法

在从南佛罗里达大学健康糖尿病健康生活之家招募的一个前瞻性队列中,对Livongo糖尿病项目在12个月内对糖化血红蛋白(HbA)、血糖范围和抑郁筛查调查结果(患者健康问卷-2 [PHQ-2])的影响进行评估。任何年龄≥18岁且诊断为糖尿病的患者均被邀请自愿加入该项目。分析采用针对纳入研究的成员的前后设计。数据在门诊就诊时收集,并通过Livongo血糖仪远程收集。

结果

共有86名成年人加入了Livongo糖尿病项目,其中49%(42/86)为女性,平均年龄50(标准差15)岁,56%(48/86)患有2型糖尿病,69%(59/86)使用胰岛素。该组中糖化血红蛋白平均下降0.66%(P = 0.17),所有参与者在12个月时糖化血红蛋白均有所下降。同时,血糖检测值<70 mg/dL的情况减少了17%。未使用胰岛素的2型糖尿病参与者89%的时间血糖值处于目标范围(70 - 180 mg/dL)。使用胰岛素的2型糖尿病参与者68%的时间处于目标范围,1型糖尿病参与者58%的时间处于目标范围。在研究期间,平均PHQ - 2得分下降了0.56分。

结论

与项目开始时相比,在门诊临床环境中为参与者提供具备实时反馈功能的蜂窝式血糖仪,并能获得认证糖尿病教育者的指导,可使平均血糖值得到改善,低血糖发作次数减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/6803884/f52c72f4e9e7/diabetes_v4i4e14799_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验